{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:37:27Z","timestamp":1794436647918,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The emergence of multidrug-resistant (MDR) bacterial pathogens is an alarming global health threat that demands new therapeutic strategies beyond conventional antibiotics. Here, we present a rationally designed antimicrobial peptide (AMP) derived from mammalian cathelicidins and defensins that selectively targets bacterial membranes with low cytotoxicity toward mammalian cells. Circular dichroism spectroscopy revealed that the peptide adopts an \u03b1-helical conformation upon membrane interaction, a key feature of its mechanism. Surface plasmon resonance and isothermal titration calorimetry demonstrated high-affinity and selective binding to bacterial lipid membranes. Functionally, the peptide was strongly bactericidal against clinical MDR\n                    <jats:italic>Escherichia coli<\/jats:italic>\n                    (\n                    <jats:italic>E. coli<\/jats:italic>\n                    ) and clinically important ESKAPE pathogens (\n                    <jats:italic>Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa,<\/jats:italic>\n                    and\n                    <jats:italic>Enterobacter<\/jats:italic>\n                    spp.). Compared with the parent peptide LL-37, our AMP exhibited lower minimum inhibitory concentrations (MICs) and faster bactericidal kinetics across both Gram-negative and Gram-positive strains. Calcein leakage assays, showing effective membrane disruption. Importantly, cytotoxicity experiments with human epithelial (Caco-2) and immune (THP-1) cells indicated low cytotoxicity at concentrations exceeding bactericidal levels, supporting a favorable therapeutic window. ELISA quantifications of cytokines (IL-6, TNF-\u03b1) further suggested immunomodulatory effects at bactericidal concentrations. Transcriptomic profiling of\n                    <jats:italic>E. coli<\/jats:italic>\n                    treated with sub-lethal concentrations of the peptide exhibited upregulation of bacterial stress response pathways and downregulation of vital metabolic processes, reflecting the complex antimicrobial action of the peptide. Collectively, these findings highlight this LL-37-derived AMP as a promising candidate for treating MDR bacterial infections caused by\n                    <jats:italic>E. coli<\/jats:italic>\n                    and ESKAPE pathogens and for guiding the development of next-generation antimicrobial agents.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-22890-7","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:17:44Z","timestamp":1760606264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Biophysical and transcriptomic characterization of LL-37-derived antimicrobial peptide targeting multidrug-resistant Escherichia coli and ESKAPE pathogens"],"prefix":"10.1038","volume":"15","author":[{"given":"Omar","family":"Eladl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"22890_CR1","doi-asserted-by":"crossref","unstructured":"Salam, M. A. et al. Antimicrobial resistance: A growing serious threat for global public health. Healthcare (Basel) 11, 1946 (2023).","DOI":"10.3390\/healthcare11131946"},{"key":"22890_CR2","doi-asserted-by":"crossref","unstructured":"EClinicalMedicine. Antimicrobial resistance: a top ten global public health threat. EClinicalMedicine 41, 101221 (2021).","DOI":"10.1016\/j.eclinm.2021.101221"},{"key":"22890_CR3","doi-asserted-by":"crossref","unstructured":"Manyi-Loh, C., Mamphweli, S., Meyer, E. & Okoh, A. Antibiotic use in agriculture and its consequential resistance in environmental sources: Potential public health implications. Molecules 23, (2018).","DOI":"10.3390\/molecules23040795"},{"key":"22890_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1177\/2042098614554919","volume":"5","author":"C Llor","year":"2014","unstructured":"Llor, C. & Bjerrum, L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. Ther. Adv. Drug Saf. 5, 229\u2013241 (2014).","journal-title":"Ther. Adv. Drug Saf."},{"key":"22890_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrmicro818","volume":"2","author":"JB Kaper","year":"2004","unstructured":"Kaper, J. B., Nataro, J. P. & Mobley, H. L. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2, 123\u2013140 (2004).","journal-title":"Nat. Rev. Microbiol."},{"key":"22890_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.vhri.2021.03.001","volume":"25","author":"K Iskandar","year":"2021","unstructured":"Iskandar, K. et al. Economic burden of urinary tract infections from antibiotic-resistant Escherichia coli among hospitalized adult patients in Lebanon: A prospective cohort study. Value Health Reg. Issues 25, 90\u201398 (2021).","journal-title":"Value Health Reg. Issues"},{"key":"22890_CR7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s13756-020-00863-x","volume":"9","author":"MC MacKinnon","year":"2020","unstructured":"MacKinnon, M. C. et al. Evaluation of the health and healthcare system burden due to antimicrobial-resistant Escherichia coli infections in humans: a systematic review and meta-analysis. Antimicrob. Resist. Infect. Control 9, 200 (2020).","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"22890_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115257","volume":"163","author":"O Eladl","year":"2025","unstructured":"Eladl, O. CRISPR interference-mediated silencing of pro-inflammatory genes in autoimmune models: functional and biophysical evaluation with sustained effects in primary human PBMCs. Int. Immunopharmacol. 163, 115257 (2025).","journal-title":"Int. Immunopharmacol."},{"key":"22890_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ymeth.2025.07.006","volume":"242","author":"O Eladl","year":"2025","unstructured":"Eladl, O. Circularization enhances RNA aptamer binding and Stability: Evidence from in-cell NMR. Methods 242, 72\u201379 (2025).","journal-title":"Methods"},{"key":"22890_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fcimb.2016.00194","volume":"6","author":"M Mahlapuu","year":"2016","unstructured":"Mahlapuu, M., H\u00e5kansson, J., Ringstad, L. & Bj\u00f6rn, C. Antimicrobial peptides: An emerging category of therapeutic agents. Front. Cell. Infect. Microbiol. 6, 194 (2016).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"22890_CR11","first-page":"445","volume":"95","author":"IE Mba","year":"2022","unstructured":"Mba, I. E. & Nweze, E. I. Antimicrobial peptides therapy: An emerging alternative for treating drug-resistant bacteria. Yale J. Biol. Med. 95, 445\u2013463 (2022).","journal-title":"Yale J. Biol. Med."},{"key":"22890_CR12","doi-asserted-by":"publisher","first-page":"7459","DOI":"10.1021\/acs.jmedchem.4c03167","volume":"68","author":"T Xu","year":"2025","unstructured":"Xu, T. et al. Development of membrane-targeting osthole derivatives containing pyridinium Quaternary ammonium moieties with potent anti-methicillin-resistant Staphylococcus aureus properties. J. Med. Chem. 68, 7459\u20137475 (2025).","journal-title":"J. Med. Chem."},{"key":"22890_CR13","doi-asserted-by":"publisher","first-page":"29373","DOI":"10.1038\/s41598-025-12791-0","volume":"15","author":"O Eladl","year":"2025","unstructured":"Eladl, O. In-cell NMR reveals the first direct observation of endogenous interaction between HIV Tat protein and Tat RNA aptamer in human cells. Sci. Rep. 15, 29373 (2025).","journal-title":"Sci. Rep."},{"key":"22890_CR14","doi-asserted-by":"publisher","first-page":"9069","DOI":"10.3390\/ijms24109069","volume":"24","author":"O Eladl","year":"2023","unstructured":"Eladl, O., Yamaoki, Y., Kondo, K., Nagata, T. & Katahira, M. Complex formation of an RNA aptamer with a part of HIV-1 Tat through induction of base triples in living human cells proven by in-cell NMR. Int. J. Mol. Sci. 24, 9069 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"22890_CR15","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1038\/nbt1267","volume":"24","author":"REW Hancock","year":"2006","unstructured":"Hancock, R. E. W. & Sahl, H.-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 24, 1551\u20131557 (2006).","journal-title":"Nat. Biotechnol."},{"key":"22890_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12967-025-06321-9","volume":"23","author":"S Zheng","year":"2025","unstructured":"Zheng, S. et al. Antimicrobial peptide biological activity, delivery systems and clinical translation status and challenges. J. Transl. Med. 23, 292 (2025).","journal-title":"J. Transl. Med."},{"key":"22890_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1039\/D2CC05576G","volume":"59","author":"O Eladl","year":"2022","unstructured":"Eladl, O., Yamaoki, Y., Kondo, K., Nagata, T. & Katahira, M. Detection of interaction between an RNA aptamer and its target compound in living human cells using 2D in-cell NMR. Chem. Commun. (Camb.) 59, 102\u2013105 (2022).","journal-title":"Chem. Commun. (Camb.)"},{"key":"22890_CR18","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s44259-025-00123-1","volume":"3","author":"N Gargate","year":"2025","unstructured":"Gargate, N., Laws, M. & Rahman, K. M. Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria. NPJ Antimicrob. Resist. 3, 50 (2025).","journal-title":"NPJ Antimicrob. Resist."},{"key":"22890_CR19","doi-asserted-by":"crossref","unstructured":"Baindara, P. Antimicrobial peptides: An emerging hope in the era of new infections and resistance. Antibiotics (Basel) 14, (2025).","DOI":"10.3390\/books978-3-7258-3959-9"},{"key":"22890_CR20","first-page":"1095","volume":"44","author":"J Mwangi","year":"2023","unstructured":"Mwangi, J., Kamau, P. M., Thuku, R. C. & Lai, R. Design methods for antimicrobial peptides with improved performance. Zool. Res. 44, 1095\u20131114 (2023).","journal-title":"Zool. Res."},{"key":"22890_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117297","volume":"242","author":"O Eladl","year":"2025","unstructured":"Eladl, O. Molecular glues and PROTACs in targeted protein degradation: mechanisms, advances, and therapeutic potential. Biochem. Pharmacol. 242, 117297 (2025).","journal-title":"Biochem. Pharmacol."},{"key":"22890_CR22","doi-asserted-by":"publisher","first-page":"10011","DOI":"10.3390\/ijms221810011","volume":"22","author":"L Falcigno","year":"2021","unstructured":"Falcigno, L. et al. Key physicochemical determinants in the antimicrobial peptide RiLK1 promote amphipathic structures. Int. J. Mol. Sci. 22, 10011 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"22890_CR23","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.3390\/ijms21175973","volume":"21","author":"I Nagaoka","year":"2020","unstructured":"Nagaoka, I., Tamura, H. & Reich, J. Therapeutic potential of cathelicidin peptide LL-37, an antimicrobial agent, in a Murine sepsis model. Int. J. Mol. Sci. 21, 5973 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"22890_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2022.105523","volume":"145","author":"M Yoosefian","year":"2022","unstructured":"Yoosefian, M., Moghani, M. Z. & Juan, A. In silico evaluation of atazanavir as a potential HIV main protease inhibitor and its comparison with new designed analogs. Comput. Biol. Med. 145, 105523 (2022).","journal-title":"Comput. Biol. Med."},{"key":"22890_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jdsr.2010.11.001","volume":"47","author":"K Okumura","year":"2011","unstructured":"Okumura, K. Cathelicidins\u2014Therapeutic antimicrobial and antitumor host defense peptides for oral diseases. Jpn. Dent. Sci. Rev. 47, 67\u201381 (2011).","journal-title":"Jpn. Dent. Sci. Rev."},{"key":"22890_CR26","doi-asserted-by":"publisher","first-page":"1405760","DOI":"10.3389\/fmicb.2024.1405760","volume":"15","author":"MES Guerra","year":"2024","unstructured":"Guerra, M. E. S. et al. Recent advances in the therapeutic potential of cathelicidins. Front. Microbiol. 15, 1405760 (2024).","journal-title":"Front. Microbiol."},{"key":"22890_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1107\/S0909049511038982","volume":"19","author":"R Hussain","year":"2012","unstructured":"Hussain, R., J\u00e1vorfi, T. & Siligardi, G. Circular dichroism beamline B23 at the Diamond Light Source. J. Synchrotron Radiat. 19, 132\u2013135 (2012).","journal-title":"J. Synchrotron Radiat."},{"key":"22890_CR28","doi-asserted-by":"crossref","unstructured":"Boonen, A. et al. Development of a novel SPR assay to study CXCR4-ligand interactions. Biosensors (Basel) 10, 150 (2020).","DOI":"10.3390\/bios10100150"},{"key":"22890_CR29","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jpha.2017.12.008","volume":"8","author":"R Karlsson","year":"2018","unstructured":"Karlsson, R., Fridh, V. & Frostell, \u00c5. Surrogate potency assays: Comparison of binding profiles complements dose response curves for unambiguous assessment of relative potencies. J. Pharm. Anal. 8, 138\u2013146 (2018).","journal-title":"J. Pharm. Anal."},{"key":"22890_CR30","doi-asserted-by":"crossref","unstructured":"Klu\u010d\u00e1kov\u00e1, M. & Krousk\u00e1, J. Microcalorimetry as an effective tool for the determination of thermodynamic characteristics of fulvic\u2013drug interactions. Processes (Basel) 13, 49 (2024).","DOI":"10.3390\/pr13010049"},{"key":"22890_CR31","unstructured":"Riss, T. L. et al. Cell viability assays. in Assay Guidance Manual (Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda (MD), 2004)."},{"key":"22890_CR32","unstructured":"Alhajj, M., Zubair, M. & Farhana, A. Enzyme linked immunosorbent assay. in StatPearls (StatPearls Publishing, Treasure Island (FL), 2025)."},{"key":"22890_CR33","unstructured":"Tierrafr\u00eda, V. H. et al. RegulonDB 11.0: Comprehensive high-throughput datasets on transcriptional regulation in Escherichia coli K-12. Microb. Genom. 8, (2022)."},{"key":"22890_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/nar\/27.1.29","volume":"27","author":"H Ogata","year":"1999","unstructured":"Ogata, H. et al. KEGG: Kyoto Encyclopedia of genes and genomes. Nucleic Acids Res. 27, 29\u201334 (1999).","journal-title":"Nucleic Acids Res."},{"key":"22890_CR35","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3389\/fimmu.2020.01137","volume":"11","author":"MR Scheenstra","year":"2020","unstructured":"Scheenstra, M. R., van Harten, R. M., Veldhuizen, E. J. A., Haagsman, H. P. & Coorens, M. Cathelicidins modulate TLR-activation and inflammation. Front. Immunol. 11, 1137 (2020).","journal-title":"Front. Immunol."},{"key":"22890_CR36","doi-asserted-by":"publisher","first-page":"8349712","DOI":"10.1155\/2020\/8349712","volume":"2020","author":"B Yang","year":"2020","unstructured":"Yang, B. et al. Significance of LL-37 on immunomodulation and disease outcome. Biomed Res. Int. 2020, 8349712 (2020).","journal-title":"Biomed Res. Int."},{"key":"22890_CR37","doi-asserted-by":"crossref","unstructured":"Grassi, L. et al. The anti-microbial peptide (Lin-SB056\u20131)2-K reduces pro-inflammatory cytokine release through interaction with Pseudomonas aeruginosa lipopolysaccharide. Antibiotics (Basel) 9, (2020).","DOI":"10.3390\/antibiotics9090585"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22890-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22890-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22890-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:17:48Z","timestamp":1760606268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22890-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22890"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22890-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study did not involve human participants or animals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36126"}}